Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel versus vinflunine in previously treated advanced urothelial carcinoma
NL-OMON38902Phase 3Recruiting
- Sponsor
- SOLTI
- Start
- Sep 2013
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma (TCC) and bladder cancer comparing Cabazitaxel with Vinflunine (2 arms). Primary endpoints: Objective response rate and Overall survival. Started Sep 2013; status: recruiting.
02
Drugs
cabazitaxelvinflunine
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON38902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38902.